Biobijou바이오비쥬

Biobijou's trailing profits look strong on filed numbers, but the share price sits well below its 52-week high and the stock carries a high valuation.

Biobijou is an export-focused maker of skin booster and hyaluronic acid filler products, with its own plant in Hanam and OEM work for brand customers. On trailing twelve months to H1 2026 it reported revenue of ₩28.6B...

What stands out

• Trailing revenue is about ₩28.6B with operating income of about ₩5.0B, an operating margin of 17.5%, up from 14.8% in 2025.
• Trailing net income of about ₩6.5B is higher than operating income, so non-operating items or one-offs may be contributing; the data does not break this down.
• At a ₩12,330 close the shares trade on about 27.9x trailing earnings and 6.4x sales, and the 52-week range is ₩5,230 to ₩16,090.
• Over three months the stock is up 38.1%, but over one year it is down 20.1%.
• Recent filings include a share buyback, a share cancellation, and a convertible bond issue completed in September 2026, while foreign ownership fell from 0.6% to 0.4% over 60 days.

What to watch

• Half-year and quarterly results for the coming periods, since the trailing figures are the only profit view in the data.
• Dilution and terms from the first convertible bond issue, which the filings cover but the data does not detail.
• Planned Japan entry for the Celivion product in the first half of next year, per the CEO's comments; terms with the local partner are still being finalised.